Search

Your search keyword '"Idrizi, Alma"' showing total 14 results
Start Over Author "Idrizi, Alma" Publication Year Range Last 3 years
14 results on '"Idrizi, Alma"'

2. Association of multiple retinal nodular hamartomas and "confetti" skin lesions with end-stage renal disease in patients with tuberous sclerosis

Author

Prelevic, Vladimir, Juric, Ivana, Bevc, Sebastijan, Marcun-Varda, Natasa, Aleckovic-Halilovic, Mirna, Mesic, Enisa, Bilic, Hrvoje, Grujicic, Milorad, Zabic, Igor, Josipovic, Josipa, Vujicic, Bozidar, Marinaki, Smaragdi, Simic-Ogrizovic, Sanja, Milinkovic, Marija, Azasevac, Tijana, Idrizi, Alma, Arnol, Miha, Radunovic, Danilo, Antunovic, Tanja, and Jukic, Nikolina Basic-

Published
2023
Full Text
View/download PDF

5. The ERA Registry Annual Report 2021: a summary

Author

Boerstra, Brittany A, primary, Boenink, Rianne, additional, Astley, Megan E, additional, Bonthuis, Marjolein, additional, Abd ElHafeez, Samar, additional, Arribas Monzón, Federico, additional, Åsberg, Anders, additional, Beckerman, Pazit, additional, Bell, Samira, additional, Cases Amenós, Aleix, additional, Castro de la Nuez, Pablo, additional, ten Dam, Marc A G J, additional, Debska-Slizien, Alicja, additional, Gjorgjievski, Nikola, additional, Giudotti, Rebecca, additional, Helve, Jaakko, additional, Hommel, Kristine, additional, Idrizi, Alma, additional, Indriðason, Ólafur S, additional, Jarraya, Faiçal, additional, Kerschbaum, Julia, additional, Komissarov, Kirill S, additional, Kozliuk, Nadiia, additional, Kravljaca, Milica, additional, Lassalle, Mathilde, additional, De Meester, Johan M, additional, Ots-Rosenberg, Mai, additional, Plummer, Zoe, additional, Radunovic, Danilo, additional, Razvazhaieva, Olena, additional, Resic, Halima, additional, Rodríguez Arévalo, Olga Lucía, additional, Santiuste de Pablos, Carmen, additional, Seyahi, Nurhan, additional, Slon-Roblero, María Fernanda, additional, Stendahl, Maria, additional, Tolaj-Avdiu, Miloreta, additional, Trujillo-Alemán, Sara, additional, Ziedina, Ieva, additional, Ziginskiene, Edita, additional, Ortiz, Alberto, additional, Jager, Kitty J, additional, Stel, Vianda S, additional, and Kramer, Anneke, additional

Published
2023
Full Text
View/download PDF

6. The ERA Registry Annual Report 2021: a summary.

Author

Boerstra, Brittany A, Boenink, Rianne, Astley, Megan E, Bonthuis, Marjolein, ElHafeez, Samar Abd, Monzón, Federico Arribas, Åsberg, Anders, Beckerman, Pazit, Bell, Samira, Amenós, Aleix Cases, Nuez, Pablo Castro de la, Dam, Marc A G J ten, Debska-Slizien, Alicja, Gjorgjievski, Nikola, Giudotti, Rebecca, Helve, Jaakko, Hommel, Kristine, Idrizi, Alma, Indriðason, Ólafur S, and Jarraya, Faiçal

Subjects
CORPORATION reports, RENAL replacement therapy, CHRONIC kidney failure, KIDNEY transplantation, PERITONEAL dialysis, IGA glomerulonephritis
Abstract

Background The European Renal Association (ERA) Registry collects data on kidney replacement therapy (KRT) in patients with end-stage kidney disease (ESKD). This paper is a summary of the ERA Registry Annual Report 2021, including a comparison across treatment modalities. Methods Data was collected from 54 national and regional registries from 36 countries, of which 35 registries from 18 countries contributed individual patient data and 19 registries from 19 countries contributed aggregated data. Using this data, incidence and prevalence of KRT, kidney transplantation rates, survival probabilities and expected remaining lifetimes were calculated. Result In 2021, 533.2 million people in the general population were covered by the ERA Registry. The incidence of KRT was 145 per million population (pmp). In incident patients, 55% were 65 years or older, 64% were male, and the most common primary renal disease (PRD) was diabetes (22%). The prevalence of KRT was 1040 pmp. In prevalent patients, 47% were 65 years or older, 62% were male, and the most common PRDs were diabetes and glomerulonephritis/sclerosis (both 16%). On 31 December 2021, 56% of patients received haemodialysis, 5% received peritoneal dialysis, and 39% were living with a functioning graft. The kidney transplantation rate in 2021 was 37 pmp, a majority coming from deceased donors (66%). For patients initiating KRT between 2012–2016, 5-year survival probability was 52%. Compared to the general population, life expectancy was 65% and 68% shorter for males and females receiving dialysis, and 40% and 43% shorter for males and females living with a functioning graft. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. The ERA Registry Annual Report 2020: a summary

Author

Astley, Megan E, primary, Boenink, Rianne, additional, ElHafeez, Samar Abd, additional, Trujillo-Alemán, Sara, additional, Arribas, F, additional, Åsberg, Anders, additional, Beckerman, Pazit, additional, Bell, Samira, additional, Bouzas-Caamaño, María Encarnación, additional, Farnés, Jordi Comas, additional, Galvão, Ana Amélia, additional, Gjorgjievski, Nikola, additional, Kelmendi, Vjollca Godanci, additional, Guidotti, Rebecca, additional, Helve, Jaakko, additional, Idrizi, Alma, additional, Indriðason, Ólafur S, additional, Ioannou, Kyriakos, additional, Kerschbaum, Julia, additional, Komissarov, Kirill, additional, Castro de la Nuez, Pablo, additional, Lassalle, Mathilde, additional, Nordio, Maurizio, additional, Arévalo, Olga Lucía Rodríguez, additional, Santiuste, Carmen, additional, Seyahi, Nurhan, additional, Roblero, María Fernanda Slon, additional, Steenkamp, Retha, additional, ten Dam, Marc A G J, additional, Zakharova, Elena V, additional, Ziginskiene, Edita, additional, Bonthuis, Marjolein, additional, Stel, Vianda S, additional, Ortiz, Alberto, additional, Jager, Kitty J, additional, and Kramer, Anneke, additional

Published
2023
Full Text
View/download PDF

8. Trends in kidney transplantation rate across Europe: study from the ERA Registry

Author

Boenink, Rianne, primary, Kramer, Anneke, additional, Tuinhout, Rosalie E, additional, Savoye, Emilie, additional, Åsberg, Anders, additional, Idrizi, Alma, additional, Kerschbaum, Julia, additional, Ziedina, Ieva, additional, Ziginskiene, Edita, additional, Farrugia, Emanuel, additional, Garneata, Liliana, additional, Zakharova, Elena V, additional, Bell, Samira, additional, Arnol, Miha, additional, Segelmark, Mårten, additional, Ioannou, Kyriakos, additional, Hommel, Kristine, additional, Rosenberg-Ots, Mai, additional, Vazelov, Evgueniy, additional, Helve, Jaakko, additional, Mihály, Sándor, additional, Pálsson, Runólfur, additional, Nordio, Maurizio, additional, Gjorgjievski, Nikola, additional, de Vries, Aiko P J, additional, Seyahi, Nurhan, additional, Magadi, Winnie A, additional, Resić, Halima, additional, Kalachyk, Aleh, additional, Rahmel, Axel O, additional, Galvão, Ana A, additional, Naumovic, Radomir, additional, Lundgren, Torbjörn, additional, Arici, Mustafa, additional, de Meester, Johan M, additional, Ortiz, Alberto, additional, Jager, Kitty J, additional, and Stel, Vianda S, additional

Published
2023
Full Text
View/download PDF

9. Association of multiple retinal nodular hamartomas and "confetti" skin lesions with end-stage renal disease in patients with tuberous sclerosis

Author

Prelevic, Vladimir, primary, Juric, Ivana, additional, Bevc, Sebastijan, additional, Marcun-Varda, Natasa, additional, Aleckovic-Halilovic, Mirna, additional, Mesic, Enisa, additional, Bilic, Hrvoje, additional, Grujicic, Milorad, additional, Zabic, Igor, additional, Josipovic, Josipa, additional, Vujicic, Bozidar, additional, Marinaki, Smaragdi, additional, Simic-Ogrizovic, Sanja, additional, Milinkovic, Marija, additional, Azasevac, Tijana, additional, Idrizi, Alma, additional, Arnol, Miha, additional, Radunovic, Danilo, additional, Antunovic, Tanja, additional, and Jukic, Nikolina Basic-, additional

Published
2022
Full Text
View/download PDF

10. The ERA Registry Annual Report 2019: summary and age comparisons

Author

Boenink, Rianne, Astley, Megan E., Huijben, Jilske A., Stel, Vianda S., Kerschbaum, Julia, Ots-Rosenberg, Mai, Åsberg, Anders A., Lopot, Frantisek, Golan, Eliezer, Castro de la Nuez, Pablo, Rodríguez Camblor, Marta, Trujillo-Alemán, Sara, Ruiz San Millan, Juan Carlos, Ucio Mingo, Pablo, Díaz Gómez, Juan Manuel, Bouzas-Caamaño, M. Encarnación, Artamendi, Marta, Aparicio Madre, Manuel I, Santiuste de Pablos, Carmen, Slon Roblero, María Fernanda, Zurriaga, Oscar, Stendahl, Maria E., Bell, Samira, Idrizi, Alma, Ioannou, Kyriakos, Debska-Slizien, Alicja, Galvão, Ana A., De Meester, Johan, Resić, Halima, Hommel, Kristine, Radunovic, Danilo, Pálsson, Runolfur, Lassalle, Mathilde, Finne, Patrik, Garcia Bazaga, María De los Ángeles, Gjorgjievski, Nikola, Seyahi, Nurhan, Bonthuis, Marjolein, Ortiz, Alberto, Jager, Kitty J., Kramer, Anneke, Universitat Autònoma de Barcelona, Department of Medicine, Clinicum, Nefrologian yksikkö, Helsinki University Hospital Area, Graduate School, Medical Informatics, APH - Aging & Later Life, APH - Quality of Care, APH - Methodology, APH - Health Behaviors & Chronic Diseases, APH - Global Health, ACS - Pulmonary hypertension & thrombosis, and UAM. Departamento de Medicina

Subjects
Transplantation, patient survival, Medicina, Nephrology, 3121 General medicine, internal medicine and other clinical medicine, graft survival, dialysis, kidney transplantation, epidemiology, ESRD, 3126 Surgery, anesthesiology, intensive care, radiology
Abstract

Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, y los autores pertenecientes a la UAM, Data on renal replacement therapy (RRT) for end-stage renal disease were collected by the European Renal Association (ERA) Registry via national and regional renal registries in Europe and countries bordering the Mediterranean Sea. This article provides a summary of the 2019 ERA Registry Annual Report, including data from 34 countries and additional age comparisons. Methods: Individual patient data for 2019 were provided by 35 registries and aggregated data by 17 registries. Using these data, the incidence and prevalence of RRT, the kidney transplantation activity and the survival probabilities were calculated. In 2019, a general population of 680.8 million people was covered by the ERA Registry. Overall, the incidence of RRT was 132 per million population (p.m.p.). Of these patients, 62% were men, 54% were ≥65 years of age and 21% had diabetes mellitus as primary renal disease (PRD), and 84% had haemodialysis (HD), 11% had peritoneal dialysis (PD) and 5% had pre-emptive kidney transplantation as an initial treatment modality. The overall prevalence of RRT on 31 December 2019 was 893 p.m.p., with 58% of patients on HD, 5% on PD and 37% living with a kidney transplant. The overall kidney transplant rate was 35 p.m.p. and 29% of the kidney grafts were from a living donor. The unadjusted 5-year survival probability was 42.3% for patients commencing dialysis, 86.6% for recipients of deceased donor grafts and 94.4% for recipients of living donor grafts in the period 2010-14. When comparing age categories, there were substantial differences in the distribution of PRD, treatment modality and kidney donor type, and in the survival probabilities, The ERA Registry is funded by the ERA. This article was written by R. Boenink et al. on behalf of the ERA Registry, which is an official body of the ERA. In addition, S.B. reports personal fees from AstraZeneca, outside the submitted work; A.D.-S. reports personal fees from Astellas and Fresenius, outside the submitted work; F.L. reports personal fees from MeditesPharma, outside the submitted work; R.P. reports grants from The Iceland Centre for Research, Landspitali University Hospital Research Fund and University of Iceland Research Fund, outside the submitted work; P.F. reports grants from Finska läkaresällskapet and Liv och Hälsa, outside the submitted work; M.F.S.R. reports personal fees from Baxter and Fresenius, outside the submitted work; A.O. reports grants from Sanofi, and personal fees from Astellas, AstraZeneca, Amicus, Bayes, Fresenius Medical Care and Idorsia, outside the submitted work; and K.J.J. reports grants from ERA, during the conduct of the study

Published
2022

12. The ERA Registry Annual Report 2019: summary and age comparisons

Author

Boenink, Rianne, primary, Astley, Megan E, additional, Huijben, Jilske A, additional, Stel, Vianda S, additional, Kerschbaum, Julia, additional, Ots-Rosenberg, Mai, additional, Åsberg, Anders A, additional, Lopot, Frantisek, additional, Golan, Eliezer, additional, Castro de la Nuez, Pablo, additional, Rodríguez Camblor, Marta, additional, Trujillo-Alemán, Sara, additional, Ruiz San Millan, Juan Carlos, additional, Ucio Mingo, Pablo, additional, Díaz, Juan Manuel, additional, Bouzas-Caamaño, M Encarnación, additional, Artamendi, Marta, additional, Aparicio Madre, Manuel I, additional, Santiuste de Pablos, Carmen, additional, Slon Roblero, María Fernanda, additional, Zurriaga, Oscar, additional, Stendahl, Maria E, additional, Bell, Samira, additional, Idrizi, Alma, additional, Ioannou, Kyriakos, additional, Debska-Slizien, Alicja, additional, Galvão, Ana A, additional, De Meester, Johan M, additional, Resić, Halima, additional, Hommel, Kristine, additional, Radunovic, Danilo, additional, Pálsson, Runolfur, additional, Lassalle, Mathilde, additional, Finne, Patrik, additional, De los Ángeles-Garcia Bazaga, María, additional, Gjorgjievski, Nikola, additional, Seyahi, Nurhan, additional, Bonthuis, Marjolein, additional, Ortiz, Alberto, additional, Jager, Kitty J, additional, and Kramer, Anneke, additional

Published
2021
Full Text
View/download PDF

14. Overview of Nonspecific and Innovative Therapies with the Potential to Reduce Chronic Kidney Disease Progression.

Author

Spahia, Nereida, Rroji, Merita, Idrizi, Alma, and Barbullushi, Myftar

Subjects
CHRONIC kidney failure, HEMODIALYSIS patients, DISEASE progression, CELLULAR therapy, SCIENTIFIC community
Abstract

Management of chronic kidney disease has always been challenged by the need for therapies or interventions that prolong time to dialysis. Given the high global incidence and prevalence of chronic kidney disease, the need for cost-effective and patient-centered interventions, aiming to postpone dialysis initiation, becomes crucial. Longevity increase and prolongation of dialysis-free interval would mean improvement in quality of life for millions of people and their families worldwide. It also decreases pressure on the health system. In the last years, the efforts of the scientific community on this matter have been rewarded by the excellent results of sodium-glucose 2-co-transport inhibitors and selective aldosterone blockers on chronic kidney disease progression, and these innovations merit to be considered milestones in nephrology. Several non-specific therapies for chronic kidney disease, such as antifibrotic/anti-inflammatory, and anti-diabetic therapies targeting cellular metabolism and beyond, have an effect on the progression of chronic kidney disease. This review discusses in a comprehensive way these therapies on the view of the potential for decrease of chronic kidney disease progression. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results